



PTO/SB/C&A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Application Number	10/634,682
Filing Date	08/05/2003
First Named Inventor	Bart De Corte
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	JAB 1425 Con 1

### U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Misc.
		Number	Kind Code <sup>2</sup> (if known)			
VM	1	4,659,383		Hubele et al.	04-21-1987	Priority to same application as EP 0945443 listed below.
B	2	5,691,364		Buckman et al.	11-25-1997	
B	3	6,048,866		Hutchings et al.	04-11-2000	
VM	4	6,093,716		Davis et al.	07-25-2000	
B	5	6,197,779	B1	Andries et al.	03-06-2001	

### FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Translation	T <sup>3</sup>
		Office <sup>4</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				
B	6	EP	0945443	A1	JANSSEN PHARMACEUTICA, NV	09-29-1999	No	
VM	7	WO	98/41512	A1	CELLTECH THERAPEUTICS, LTD	09-24-1998	No	
VM	8	EP	0945442	A1	JANSSEN PHARMACEUTICA, NV	09-29-1999	No	
VM	9	WO	95/10506	A1	DU PONT MERCK PHARMACEUTICAL	04-20-1995	No	
VM	10	EP	0371139	B1	MIYASAKA, Tadashi	10-12-1994	No	
VM	11	EP	0136472	A2	CIBA-GEIGY A.G.	03-27-1985	No	
VM	12	EP	0 588 782	A1	CIBA-GEIGY A.G.	08-23-1993	Yes	
VM	13	EP	0 135 472	A2	CIBA-GEIGY A.G.	07-19-1984	English Abstract	
VM	14	EP	0834,507	A1	JANSSEN PHARMACEUTICA, NV	04-08-1998	No	

Examiner Signature	V. Balasubramanian	Date Considered	8/17/04
-----------------------	--------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3


Application Number	10/634,682
Filing Date	08/05/2003
First Named Inventor	Bart De Corte
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	JAB 1425 Con 1

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Translation	T <sup>2</sup>
M	15	ARNOLD, et al., Inhibitor conformational flexibility and positional variation are important for activity against drug-resistant virus: crystal structures of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase, 21 <sup>st</sup> European Crystallographic Meeting, Durban, South Africa, 24-29, Aug. 2003.		
M	16	ARNOLD, Conformational Flexibility of DAPYs: activity against resistant HIV, Aug. 2003.		
M	17	BLAGOVIC, et al., Validation of a Model for the Complex of HIV-1 Reverse Transcriptase with Nonnucleoside Inhibitor TMC125, J. AM. CHEM. SOC. 2003, Vol. 125, pp. 6016-6017.		
M	18	CLARK, Inhibitor conformational flexibility and positional variation are important for activity against drug-resistant virus: crystal structures of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase, 21 <sup>st</sup> European Crystallographic Meeting, Durban, S. Africa, 24-29, Aug. 2003.		
M	19	DAS, et al., Could multiple modes of binding of a potent NNRTI TMC125-R165335 explain its potency against common drug-resistant mutants?, CROI, Boston, Feb. 2003		
M	20	M-P de BETHUNE, TMC 125 resistance profiles, Resistance, Mexico, June 2003		
M	21	FURUKAWA, et al., Syntheses of Compounds related to Guanidine and their Inhibitory Action on Growth of HeLa Cells, Chem. Pharm. Bull. 9 (11), 914-921 (1951)		
M	22	GAZZARD, et al., TMC125, A Next-Generation NNRTI, Demonstrates High Potency After 7 Days Therapy in Treatment-Experienced HIV-1 Infected Individuals with Phenotypic NNRTI, CROI, Seattle, Feb. 2002.		
M	23	GAZZARD, et al., An open-label assessment of TMC 125 - a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance, AIDS 2003, Vol. 17, pp. 49-54.		
M	24	GAZZARD, et al., TMC125, a Next Generation NNRTI, Demonstrates High Potency After 7 Days Therapy in Treatment-Experienced HIV-1 Infected Individuals with Phenotypic NNRTI-Resistance, XIV International AIDS Conference, July 7-11, 2003, Barcelona, Spain		
M	25	GAZZARD, TMC 125 C207 study treatment-experienced, CROI Seattle, Feb. 2002		
M	26	GAZZARD, 7 day treatment-experienced, WAC Barcelona, Jul. 2002		
M	27	GRUZZDEV, et al., A Randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive HIV-1 infected subjects, AIDS 2003, VOL 17, pp. 2487-2494.	No	
M	28	GULICK, New Antiretroviral Drugs, Clinical Microbiology and Infectious Diseases, CMI, 9, (3) pp. 186-193 (March, 2003)		
M	29	LANGE, TMC 125 decay rate vs ERA, CROI Seattle, Feb. 2002		
M	30	LEW, Potency & multiple binding modes of TMC 125, CROI Boston, Feb. 2003		
M	31	LUDOVICI, et al., Evolution of Anti-HIV Drug Candidates. Part 3: Diarylpyrimidine (DAPY) Analogues, Bioorganic & Medical Chemistry Letters 11, 2001, pp. 2235-2239.		
M	32	SANKATSING, et al., TMC 125 Monotherapy for One Week Results in a Similar Initial Rate of Decline of HIV-1 RNA as Therapy With a 5-Drug Regimen, CROI, Seattle, Feb., 2002.		
M	33	SANKATSING, et al., TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen, AIDS 2003, Vol. 17, pp. 2623-2627.		

Examiner Signature	V. Balasubramanian	Date Considered	8/17/04
--------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (end by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

<b>Application Number</b>	10/634,682
<b>Filing Date</b>	08/05/2003
<b>First Named Inventor</b>	Bart De Corte
<b>Group Art Unit</b>	1614
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	JAB 1425 Con 1

(use as many sheets as necessary)

Sheet 3 of 3

Examiner Signature	<i>H. Balasubramanian</i>	Date Considered	8/17/04
-----------------------	---------------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* Applicant's unique citation designation number (optional). \* See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.